ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 0942 • ACR Convergence 2025

    Sodium-Glucose Co-Transporter 2 Inhibitors Modulate Renal Injury and Autoreactive Plasma Cells in Lupus

    Jennifer Nicholson1, Maria Ossa-Echeverri1, Arpitha Haranahalli Shivarudrappa1, Mark Lusco1, Maria de la Luz Garcia-Hernandez2, John Looney1, Jennifer Anolik3 and Javier Rangel-Moreno1, 1University of Rochester, Rochester, NY, 2University of Rochester, West Henrietta, NY, 3University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Though immune targeted therapies have improved outcomes in lupus nephritis, a significant number of patients experience renal damage and even progression to end stage…
  • Abstract Number: 0713 • ACR Convergence 2025

    Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms

    Adil Vural1, Chao Zhang2, Yaseen Kinanah1, Cassandra Calabrese3 and Adam Brown4, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland Heights, OH, 3Cleveland Clinic Foundation, Cleveland Heights, OH, 4Cleveland Clinic, Shaker Heights, OH

    Background/Purpose: ANCA associated vasculitis (AAV) is a severe autoimmune disorder with substantial morbidity and mortality. Establishing the diagnosis might be challenging due to the existence…
  • Abstract Number: 0647 • ACR Convergence 2025

    Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus: an open-label pilot study

    Jinxia Zhao, Xiaoying Zhang, Xinyi Li, Hui Wei, Rui Liu, Lin Sun, Zhaohua Li, Wei Guo and Rong Mu, Peking University Third Hospital, Beijing, China (People's Republic)

    Background/Purpose: This pilot study aims to evaluate the preliminary efficacy and safety of autologous anti-CD19 chimeric antigen receptor T cell (CAR T) named IM19 therapy…
  • Abstract Number: 0628 • ACR Convergence 2025

    Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus

    Panagiotis Garantziotis1, Dionysis Nikolopoulos2, Spyridon Katechis3, Alp Temiz4, Danae-Mona Nöthling1, Christina Adamichou5, Prodromos Sidiropoulos6, Georg Schett7, Fanouriakis Antonis3, Dimitrios Boumpas8 and George Bertsias9, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 2Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 3National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 4Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, 5Medical School University of Crete, Heraklion, Greece, Heraklion, Germany, 6Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece, 7Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 8Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, 9Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece

    Background/Purpose: Organ damage drives morbidity and mortality in systemic lupus erythematosus (SLE), yet no validated tools exist to predict early damage. We aimed to develop…
  • Abstract Number: 0610 • ACR Convergence 2025

    The Role of Active Nephritis, Compared to Active Non-Renal SLE, in Pregnancy Outcomes

    Emma Trachman1, Amanda Eudy2 and Megan Clowse3, 1Duke University, Durham, NC, 2Duke University, Raleigh, NC, 3Duke University, Chapel Hill, NC

    Background/Purpose: The ACR recommends against pregnancy in patients with SLE with high disease activity. These recommendations do not distinguish between the various manifestations of active…
  • Abstract Number: 0593 • ACR Convergence 2025

    Genetic Risk Profiles Predict Clinical Heterogeneity in Systemic Lupus Erythematosus

    Nina Oparina1, Sarah Reid1, Ahmne Sayadi1, Maija-Leena Eloranta1, Martina Frodlund2, Karoline Lerang3, Andreas Jönsen4, Øyvind Molberg3, Solbritt Rantapää-Dahlqvist5, Anna Rudin6, Chrisopher Sjöwall7, Anders Bengtsson8, Lars Rönnblom1 and Dag Leonard1, 1Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Linkoping, Sweden, 3Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 4Department of Clinical Sciences, Lund University,, Lund, Sweden, 5Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 6Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, 7Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, 8Department of Clinical Sciences, Lund University, Lund, Sweden

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical manifestations. Genetic predisposition contributes significantly to its pathogenesis, and higher genetic load is…
  • Abstract Number: 0793 • ACR Convergence 2025

    The weight of the past: how trauma and resilience shape medication adherence in SLE

    Kai Sun1, Sofia Pozsonyiova1, Amanda Eudy2, Megan Clowse3, Rebecca Sadun1, Mithu Maheswaranathan4, Jayanth Doss5, Nathaniel Harris6, Lisa Criscione-Schreiber4, Connor Drake4, Tamara Somers7, Ralph Snyderman8 and Jennifer Rogers4, 1Duke University, Durham, NC, 2Duke University, Raleigh, NC, 3Duke University, Chapel Hill, NC, 4Duke University School of Medicine, Durham, 5Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham, NC, 6Duke University Medical Center, Durham, NC, 7Duke University School of Medicine, Durham, NC, 8Duke Center for Personalized Health Care, Durham, NC

    Background/Purpose: Medication adherence in SLE is suboptimal and contributes to increased disease activity, organ damage, and mortality. Trauma exposure is common among those with SLE…
  • Abstract Number: 0206 • ACR Convergence 2025

    Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies

    Nadia Emi Aikawa1, Julia Medeiros2, Sandra G Pasoto3, Ana C Medeiros-Ribeiro3, Luciana Parente Costa Seguro4, Ana Paula Luppino-Assad5, Emily Figueiredo Neves Yuki6, Lissiane Guedes7, Clovis Artur Silva8 and Eloisa Bonfa4, 1Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, 3Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 4Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 5Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, 6Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, 7Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, 8University of São Paulo, São Paulo, São Paulo, Brazil

    Background/Purpose: Recombinant zoster vaccine (RZV), represents a major advancement in the prevention of herpes zoster in autoimmune rheumatic diseases (ARD) patients. However, RVZ efficacy depends…
  • Abstract Number: 1509 • ACR Convergence 2025

    Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study

    Shuzo Sato, Kaito Moriuchi, So Yamamoto, Hiroki Nibu, Takahito Sakamoto, Shotaro Ogawa, Kenji Saito, Yuya Sumichika, Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku and Tomoyuki Asano, Fukushima Medical University, Fukushima, Fukushima, Japan

    Background/Purpose: Past reports have shown that serositis is a risk factor for organ damage in patients with SLE. However, the distinct clinical features of newly…
  • Abstract Number: 2693 • ACR Convergence 2025

    CAR T-cell Therapy in SLE: A Systematic Review

    Alberto Nordmann-Gomes1, Leila Khalili2, Wei Tang3, Laura Geraldino-Pardilla4, Yevgeniya Gartshteyn5, Robert Clancy4, Stephen Suh6, Maya Souvignier6, Michel Sadelain6 and Anca Askanase2, 1Columbia University Irving Medical Center, New York, NY, 2Columbia University Medical Center, New York, NY, 3Westchester Medical Center, Valhalla, NY, 4Columbia University, New York, NY, 5Columbia University Medical Center, Glen Rock, NJ, 6Columbia University Irving Medical Center, New York City, NY

    Background/Purpose: CAR T-cell therapy is poised to revolutionize the treatment of systemic lupus erythematosus (SLE). Recently, several authors have reported their experience using CAR T-cell…
  • Abstract Number: 2600 • ACR Convergence 2025

    Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution

    Nicholas Sugiarto1, Michelle Curtis2, Siddarth Gurajala2, Thomas Eisenhaure3, Qian Xiao4, Joseph Mears5, Arnon Arazi6, Paul Hoover7, Celine Berthier8, Saori Sakaue9, Andrea Fava10, David Hildeman11, E. Steve Woodle12, Brad Rovin13, Jennifer Barnas14, Maria Dall'Era15, Chaim Putterman16, Diane Kamen17, Maureen McMahon18, Jennifer Grossman19, Kenneth Kalunian20, Jeffrey Hodgin21, Fernanda Payan Schober22, Mariko Ishimori23, Michael Weisman23, William Apruzzese24, Joel Guthridge25, Michael Brenner26, Jennifer Anolik27, David Wofsy28, Judith James25, Deepak Rao7, Anne Davidson29, Michelle Petri30, Jill Buyon31, Nir Hacohen32, Betty Diamond33 and Soumya Raychaudhuri7, 1Harvard Medical School, Brookline, MA, 2Harvard Medical School, Boston, 3Broad Institute, Cambridge, MA, 4Harvard Medical School, Boston, MA, 5Michigan University, Ann Arbor, MI, 6Feinstein Institutes for Medical Research, Acton, MA, 7Brigham and Women's Hospital, Boston, MA, 8University of Michigan, Ann Arbor, MI, 9University of Washington, Yokohama, Japan, 10Johns Hopkins University, Baltimore, MD, 11Cincinnati Children's Hospital, Cincinnati, OH, 12UC Health, Cincinnati, 13The Ohio State University, Columbus, OH, 14University of Rochester, Rochester, NY, 15Division of Rheumatology, University of California, San Francisco, CA, 16Albert Einstein College of Medicine, Safed, Israel, 17Medical University of South Carolina, Johns Island, SC, 18UCLA David Geffen School of Medicine, Los Angeles, CA, 19UCLA, Sherman Oaks, CA, 20UC San Diego, La Jolla, CA, 21University of Michigan, Ann Arbor, 22TTUHSC, El Paso, TX, 23Cedars-Sinai Medical Center, Los Angeles, CA, 24Pfizer, Boston, 25Oklahoma Medical Research Foundation, Oklahoma City, OK, 26Brigham and Women's Hospital, Harvard Medical School, Newton, MA, 27University of Rochester Medical Center, Rochester, NY, 28University of California San Francisco, SF, CA, 29Feinstein Institutes for Medical Research, Manhasset, NY, 30Johns Hopkins University School of Medicine, Timonium, MD, 31NYU Grossman School of Medicine, New York, NY, 32Broad Institute of MIT Harvard, Cambridge, MA, 33The Feinstein Institutes for Medical Research, Manhasset, NY

    Background/Purpose: Lupus nephritis (LN) is a heterogeneous disease driven by diverse immune and tissue cell types. We defined the cell states in the tissue and…
  • Abstract Number: 2466 • ACR Convergence 2025

    Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis

    Richard Furie1, Neel Anand2, Shraddha Desai3, Eric Lowe4, Tony Muchamuel3, Kiruthi Palaniswamy2, Rachel Peterson2, Kathryn Ray2, Zung To2, Jennifer Whang2 and Richard Leff5, 1Division of Rheumatology, Northwell Health, Great Neck, NY, 2Kezar Life Sciences, Inc, South San Francisco, CA, 3Kezar Life Sciences, Inc, South San Francisco, 4Kezar Life Sciences, South San Francisco, CA, 5Richard L Leff MD LLC, Chadds Ford, PA

    Background/Purpose: Zetomipzomib (zeto), a selective immunoproteasome inhibitor, has previously shown anti-inflammatory activity in patients (pts) with SLE and LN in the open-label MISSION study. The…
  • Abstract Number: 2448 • ACR Convergence 2025

    Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus

    Haiting Wang1, Liling Zhao2, Shuang Ye3 and Shaoying Yang2, 1Renji Hospital, Rockville, MD, 2Renji hospital, Shanghai, China (People's Republic), 3Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)

    Background/Purpose: Rituximab (RTX) has been commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE), yet real-world data concerning RTX…
  • Abstract Number: 2431 • ACR Convergence 2025

    Bone marrow- activity on 18F-FDG PET/CT as a Predictor of Hematologic Manifestations in Systemic Lupus Erythematosus

    Sungwon Ko1, Young-Eun Kim1, Soyoon Yoon2, Soo Min Ahn1, Ji Seon Oh1, Yong-Gil Kim1, Chang-Keun Lee3, Bin Yoo1, Dong Yun Lee4 and Seokchan Hong1, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, 2Department of Nuclear Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea, 3Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea, 4Department of Nuclear Medicine, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea

    Background/Purpose: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a noninvasive imaging modality widely used to assess inflammatory activity in various autoimmune and hematologic…
  • Abstract Number: 2411 • ACR Convergence 2025

    The 2019 EULAR/ACR and 2012 SLICC Classification Criteria for SLE Should Be Applied with Caution as Diagnostic Criteria

    Luca Mazzoleni1, Francesca Crisafulli2, Md Yuzaiful Md Yusof3, Aamir Aslam4, Andrew Barr5, Lesley-Anne Bissell6, Shouvik Dass5, Jack E Arnold7, Ed Vital8, Franco Franceschini9 and Porntip Intapiboon10, 1University of Brescia, Brescia, Italy, 2ASST Spedali Civili and University of Brescia, Brescia, Italy, 3University of Leeds, Leeds, United Kingdom, 4Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 5Leeds teaching hospitals- NHS trust, Leeds, United Kingdom, 6Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, 7Leeds Institute of Rheumatic & Musculoskeletal Medicine, Leeds, United Kingdom, 8University of Leeds, Leeds, England, United Kingdom, 9University of Brescia, Brescia, Brescia, Italy, 10Prince Of Songkla universitiy, Tambon Kohong, Thailand

    Background/Purpose: To assess the 2012 SLICC and 2019 EULAR/ACR classification criteria performance as diagnostic criteria in two cohorts of ANA-positive patients clinically suspected of having…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology